---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-002689"
form_type: "8-K"
ticker: "GRCE"
cik: "0001444192"
company_name: "Grace Therapeutics, Inc."
filed_at: "2024-01-08T23:59:59+00:00"
generated_at: "2026-06-07T02:10:05.447494+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Acasti Pharma appoints Robert J. DelAversano as principal financial and accounting officer, effective Jan 5, 2024

## Summary
- Robert J. DelAversano, 52, CPA and former VP Finance, becomes principal financial and accounting officer.
- Brian Ford removed as interim-CFO; remains as financial consultant on an as-needed basis.
- DelAversano receives $290,000 base salary, up to 30% target bonus, and 42,000 stock options at $2.125 per share.
- DelAversano joined Acasti in Nov 2023; prior experience at OncoSec and Brio Financial Group.

## SEC filing metadata
- accession: 0000950170-24-002689
- form_type: 8-K
- ticker: GRCE
- cik: 0001444192
- company_name: Grace Therapeutics, Inc.
- filed_at: 2024-01-08T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1444192/000095017024002689/0000950170-24-002689-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1444192/000095017024002689/acst-20240105.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-002689
- JSON: https://secwatch.observer/filing/0000950170-24-002689.json
- Plain text: https://secwatch.observer/filing/0000950170-24-002689.txt

## Key facts
- Executive change
  Brian Ford was removed as Interim Chief Financial Officer at Grace Therapeutics, Inc..
  - Action: removed
  - Role: Interim Chief Financial Officer
  source text: Concurrently with such appointment, the Board removed Brian Ford from the position of interim-Chief Financial Officer.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1444192/000095017024002689/0000950170-24-002689-index.htm
- Executive change
  Robert J. DelAversano was appointed as Principal Financial Officer and Principal Accounting Officer at Grace Therapeutics, Inc..
  - Action: appointed
  - Role: Principal Financial Officer and Principal Accounting Officer
  source text: On January 5, 2024, the Board of Directors (the “Board”) of Acasti Pharma Inc. (the “Company”) approved the appointment of Robert J. DelAversano, the Company's Vice President, Finance, to the roles of principal financial officer and principal accounting officer of the Company, effective immediately.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1444192/000095017024002689/0000950170-24-002689-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.